Paclitaxel and Docetaxel combinations in non-small cell lung cancer

Chest

Volumn 117, Issue 4 SUPPL. 1, 2000, Pages 144S-151S

  Belani, Chandra P ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Carboplatin; Cisplatin; Docetaxel; Non small cell lung cancer; Paclitaxel; Taxanes

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0033999225     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.4_suppl_1.144S     Document Type: Conference Paper

References (62)

1. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332:1004-1014
2. Horwitz SB. Mechanism of action of Taxol. Trends Pharmacol Sci 1992; 13:134-136
3. Chang AY, Kim K, Glick J, et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993; 85:388-394
4. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:384-388
5. Gatzemeier U, Heckmayer M, Neuhauss R, et al. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial. Semin Oncol 1995; 22(suppl): 24-28
6. Millward MJ, Bishop JF, Friedlander M, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1996; 14:142-148
7. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20(suppl):1-15
8. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654-2666
9. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995; 13:1609-1614
10. Akerley W, Choy H, Safran H, et al. Weekly paclitaxel: marked activity, diminished toxicity and platelet stimulating effect [abstract]. Lung Cancer 1997; 18(suppl):19
11. Klastersky J, Sculier JP. Cisplatin plus Taxol in non-small cell lung cancer: a dose finding trial [abstract]. Proc Am Assoc Cancer Res Annu Meet 1995; 36:A1423
12. Pirker R, Krajnik G, Zochbauer S, et al. Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC). Ann Oncol 1995; 6:833-835
13. Belli L, LeChevalier T, Gottfried M, et al. Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol Annu Meet 1995; 14:350
14. Rowinsky EK, Citardi MJ, Noe DA, et al. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 1993; 119:727-733
15. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9:1692-1703
16. Bonomi PD, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin versus Taxol (T) with cisplatin G-CSF (G) versus cisplatin in advanced non-small cell lung cancer: Eastern Cooperative Oncology Group (ECOG) [abstract]. Proc Am Soc Clin Oncol Annu Meet 1996; 15:382
17. Gelmon KA, Tolcher A, O'Reilly S, et al. Phase I/II trial of biweekly paclitaxel (Taxol) in metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol Annu Meet 1995; 14:132
18. Georgiadis MS, Brown JE, Schuler BS, et al. Phase I study of a four day continuous infusion of paclitaxel followed by cisplatin in patients with advanced lung cancer [abstract]. Proc Am Soc Clin Oncol Annu Meet 1995; 14:353
19. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7:1602-1613
20. Kramer BS, Birch R, Greco A, et al. Randomized phase II evaluation of iproplatin (CHIP) and carboplatin (CBDCA) in lung cancer. Am J Clin Oncol 1988; 11:643-645
21. Kreisman H, Ginsberg S, Propert KJ, et al. Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Cancer Treat Rep 1987; 71:1049-1052
22. Gandara DR, Wold H, Perez EA, et al. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 1989; 81:790-794
23. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group study (SWOG-9308) [abstract]. Proc Am Soc Clin Oncol Annu Meet 1996; 15:374
24. Klastersky J, Sculier JP, Bureau G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1989; 7:1087-1092
25. Belani CP, Aisner J, Hiponia D, et al. Paclitaxel and carboplatin in metastatic non-small cell lung cancer: preliminary results of a phase I study. Semin Oncol 1996; 23(suppl):19-21
26. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13:1860-1870
27. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1996; 14:2054-2060
28. Lee FH, Cabetta R, Ussekk BF, et al. New platinum complexes in clinical trials. Cancer Treat Rev 1983; 10:43-45
29. Canetta R, Franks C, Smaldone L, et al. Clinical status of carboplatin. Oncology 1987; 1:61-69
30. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol 1989; 7:1602-1613
31. Bunn PA Jr. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 1989; 16(suppl):27-33
32. Natale RB. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 1996; 23(suppl):2-6
33. Rowinsky EK, Flood WA, Sartorius SE, et al. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Semin Oncol 1995; 22(suppl):48-54
34. Schutte W, Bork I, Sucker S. Phase II trial of paclitaxel and carboplatin as firstline treatment in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol Annu Meet 1996; 15:398
35. Bunn PA Jr, Kelly K. A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol 1995; 22(suppl): 2-6
36. Giaccone G, Huizing M, Postmus PE, et al. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 1995; 22:78-82
37. Hainsworth JD, Thompson DS, Urba WJ, et al. One hour paclitaxel plus carboplatin in advanced non-small cell lung cancer (NSCLC): preliminary results of a multi-institutional phase II study [abstract]. Proc Am Soc Clin Oncol Annu Meet 1996; 15:379
38. Langer C, Kaplan R, Rosvold E, et al. Paclitaxel (P) by 1 hour (hr) infusion combined with carboplatin (C) in advanced non-small cell lung carcinoma [abstract]. Proc Am Soc Clin Oncol Annu Meet 1996; 15:396
39. Roa V, Conner A, Mitchell RB. Carboplatin and paclitaxel for chemotherapy-naive patients with advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol Annu Meet 1996; 15:404
40. Evans WK, Stewart DJ, Tomiak E, et al. Carboplatin (C) and paclitaxel (P) by one hour infusion for advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol Annu Meet 1995; 14:374
41. Kearns CM, Belani CP, Erkmen K, et al. Reduced platelet toxicity with combination carboplatin and paclitaxel; pharmacodynamic modulation of carboplatin associated thrombocytopenia [abstract]. Proc Am Soc Clin Oncol Annu Meet 1995; 14:170
42. Belani CP, Natale R, Lee JS, et al. Randomized study of cisplatin/etoposide versus paclitaxel/carboplatin in advanced and metastatic non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol Annu Meet 1998; 17:455a
43. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 1994; 70:384-387
44. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994; 12:1232-1237
45. Burris HA, Eckardt J, Fields S, et al. Phase II trials of taxotere in patients with non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol Annu Meet 1993; 12:335
46. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994; 12:1238-1244
47. Watanabe K, Yokoyama A, Furuse K, et al. Phase II trial of docetaxel in previously untreated non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol Annu Meet 1994; 13:331
48. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small lung cancer. Cancer 1995; 75:968-972
49. Lira-Puerto V, Zepeda G, Mohar A, et al. Phase-II trial of Taxotere (docetaxel) in advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol Annu Meet 1995; 14:382
50. Burris H, Eckardt J, Fields S, et al. Phase II trials of Taxotere in patients with non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol Annu Meet 1993; 12:338
51. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel (Taxotere) for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995; 13:645-651
52. Gandara DR, Vokes E, Green M, et al. Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival in a multicenter trial [abstract]. Proc Am Soc Clin Oncol Annu Meet 1996; 16:508
53. Pronk LC, Schellens JH, Planting AS, et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15:1071-1091
54. Zalcberg JR, Bishop JF, Millward MJ, et al. Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) [abstract]. Eur J Cancer 1995; 31A(suppl):S226
55. Belani CP, Bonomi P, Dobbs T, et al. Multicenter phase II trial of docetaxel and cisplatin combination in patients with non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol Annu Meet 1997; 16:221a
56. LeChevalier T, Belli L, Monnier A, et al. Phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small cell lung cancer (NSCLC): an interim analysis [abstract]. Proc Am Soc Clin Oncol Annu Meet 1995; 14:350
57. Androulakis N, Dimopoulos AM, Kourousis C, et al. First-line treatment of advanced non-small cell lung cancer (NSCLC) with docetaxel and cisplatin: a multicenter phase II study [abstract]. Proc Am Soc Clin Oncol Annu Meet 1997; 16:461a
58. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7:1602-1613
59. Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-1, 1 cyclobutane-decarboxylate platinum II. Cancer Chemother Pharmacol 1982; 9:140-147
60. Curt GA, Grygeil JJ, Corden BJ, et al. A phase I and pharmacokinetic study of diammine-cyclobutane-decarboxylate-platinum (NSC 241240). Cancer Res 1983; 43:4470-4473
61. Belani CP, Hadeed V, Ramanathan R, et al. Docetaxel and carboplatin: a phase I and pharmacokinetic trial for advanced non-hematologic malignancies [abstract]. Proc Am Soc Clin Oncol Annu Meet 1997; 16:220a
62. Belani CP, Einzig A, Bonomi P, et al. Multi-institutional phase II trial of docetaxel and carboplatin combination in patients with stage IIIB and IV non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer 1997; 18:16